{"nctId":"NCT02445326","briefTitle":"OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis","startDateStruct":{"date":"2015-04","type":"ACTUAL"},"conditions":["Chronic Allergic Conjunctivitis"],"count":73,"armGroups":[{"label":"OTX-DP","type":"EXPERIMENTAL","interventionNames":["Drug: Dexamethasone"]},{"label":"PV","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo Vehicle"]}],"interventions":[{"name":"Dexamethasone","otherNames":[]},{"name":"Placebo Vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has a positive history of ocular allergies and a positive skin test reaction to a perennial allergen and a seasonal allergen\n* Has a positive bilateral CAC reaction to a perennial allergen within minutes of instillation\n\nExclusion Criteria:\n\n* History of refractive surgery (including LASIK procedures)\n* History of retinal detachment, diabetic retinopathy, or active retinal disease\n* Presence of an active ocular infection or positive history of an ocular herpetic infection at any visit\n* Use any of the disallowed medications during the period indicated\n* History of IOP increase as a result of steroid treatment","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6","description":"Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.68","spread":"1.032"},{"groupId":"OG001","value":"2.66","spread":"0.861"}]}]}]},{"type":"PRIMARY","title":"Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6","description":"Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.87","spread":"1.040"},{"groupId":"OG001","value":"2.74","spread":"0.690"}]}]}]},{"type":"PRIMARY","title":"Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6","description":"Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.70","spread":"0.938"},{"groupId":"OG001","value":"2.74","spread":"0.679"}]}]}]},{"type":"PRIMARY","title":"Conjunctival Redness Post-CAC (Conjunctival Allergen Challenge) at Visit 6","description":"Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.52","spread":"0.641"},{"groupId":"OG001","value":"1.80","spread":"0.764"}]}]}]},{"type":"PRIMARY","title":"Conjunctival Redness Post-CAC (Conjunctival Allergen Challenge) at Visit 6","description":"Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.48","spread":"0.698"},{"groupId":"OG001","value":"1.75","spread":"0.786"}]}]}]},{"type":"PRIMARY","title":"Conjunctival Redness Post-CAC (Conjunctival Allergen Challenge) at Visit 6","description":"Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=None","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.44","spread":"0.710"},{"groupId":"OG001","value":"1.76","spread":"0.766"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":35},"commonTop":["Adverse Events"]}}}